CCM
ONCY

Connective Capital Management’s Oncolytics Biotech ONCY Stock Holding History

Connective Capital Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176K Buy
+185,712
New +$172K 0.12% 51
2026
Q1 		– Sell
-150,340
Closed -$131K – 76
2025
Q4 		$131K Buy
+150,340
New +$162K 0.08% 48

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Connective Capital Management's ONCY Position: Q2 2026 in Review

Connective Capital Management opened a new position in Oncolytics Biotech (ONCY) in Q2 2026: 185,712 shares worth $176K. The stake represents 0.12% of the portfolio and ranks #51 among its holdings. This is a return to the name: Connective Capital Management previously reported a position in ONCY as recently as Q4 2025.

Connective Capital Management first reported a position in ONCY in Q4 2025 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Connective Capital Management held 185,712 shares of Oncolytics Biotech worth $176K as of Q2 2026.
  • Oncolytics Biotech was a new Connective Capital Management position in Q2 2026.
  • Oncolytics Biotech made up 0.12% of Connective Capital Management's portfolio in Q2 2026, its #51 holding.
  • Connective Capital Management first reported a position in Oncolytics Biotech in Q4 2025 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Connective Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.